Axogen, Inc. (AXGN) SEC Filings & Earnings Calls

Integration risk: Successfully integrating BioCircuit and realizing expected revenue contributions may face challenges.

“forward-looking statements regarding Axogen’s ability to successfully integrate BioCircuit and realize the anticipated benefits of the acquisition”

Dilution from 4.91M share offering; acquisition integration risk.

“4.91M shares offered; acquisition of BioCircuit.”

Gross margin pressure from product cost inflation

“margins on products sold declined primarily due to higher product costs” · word for word

Operating loss and net loss

“(Loss) income from operations (2,156) ... Net (loss) income $ (1,516)”

Product mix shift toward lower-margin breast products may pressure gross margin.

“Gross margin performance was driven by changes in product mix caused primarily by accelerating year over year Breast growth greater than 50%.” · word for word

Net loss reported in Q2 2026 vs net income in prior year; adjusted EBITDA declined.

“Net loss was $1.5 million, compared to Net income of $0.6 million; Adjusted EBITDA $8.4M vs $9.3M.”

Continued net losses and negative EBITDA

“Net loss $(15,703) (in thousands) for 2025.”

Dependence on FDA approval for expanded indications

“Continued approval for indications of sensory nerve discontinuities (>25mm) and for mixed and motor nerve discontinuities depends on verification and description of clinical benefit in confirmatory studies.” · word for word

Concentrated ownership by single investor

“First Light Asset Management, LLC ... 5,940,632 shares ... 11.17%”

High stock-based compensation expense

“Non-cash stock-based compensation expense ... $30,112 (in thousands) for 2025.”

Net loss of $19.6M due to non-cash charges or one-time items; adjusted net income positive

“Net loss $19.6M vs adjusted net income $4.1M; difference likely due to stock-based compensation or amortization”

Tariff / Trade War Exposure

“While our direct exposure to current tariffs is limited, risk lies in the potential for these disputes to cause a broader trade war, resulting in general economic instability and uncertainty that could cause our net revenue to fluctuate.” · word for word

Net loss increased due to one-time FDA BLA costs; gross margin declined.

“Net loss for the fourth quarter of 2025 was $13.2 million ... Gross margin reflects one-time costs of approximately $1.9 million” · word for word

Patent expiration on Axoguard product line

“The material U.S. patents covering the formulations used in our Axoguard Product Line, which are held by Evergen, have expired. Expiration of these patents could adversely affect our ability to successfully execute our business strategy to maximize the value of Axoguard products and could materially and adversely impact our business, results of operations, f” · word for word

Concentrated ownership limiting liquidity

“As of December 31, 2025, approximately 27.5% of our outstanding shares of common stock were held by our officers, directors, beneficial owners of 5% or more of our securities and their respective affiliates, which adversely affects the liquidity of the trading market for our common stock.” · word for word

Dilution from equity offering

“4M shares issued; potential dilution of ~10% based on prior share count”

Reimbursement and regulatory risks

“Reimbursement expectations and regulatory approvals mentioned in forward-looking statements.”

Dependence on FDA approval of Avance Nerve Graft BLA.

“FDA approval of the BLA for Avance Nerve Graft is now anticipated by December 5, 2025.” · word for word

FDA Approval Delay Risk

“On August 22, 2025 we received a communication from the FDA stating that our submission of facility and manufacturing information, provided in response to an FDA information request, constituted a major amendment to our BLA for Avance® Nerve Graft. ... the FDA extended the PDUFA goal date to December 5, 2025.” · word for word

Government Shutdown Impact

“the ongoing U.S. government shutdown that began on October 1, 2025, has introduced additional uncertainty across the regulatory environment.” · word for word

Trade War / Tariff Risk

“While our direct exposure to current tariffs is limited, risk lies in the potential for these disputes to cause a broader trade war, resulting in general economic instability and uncertainty that could cause our net revenue to fluctuate.” · word for word